Evidence map›Paper›PMID 32605625›Full record

Observational studySubstance abuse treatment, prevention, and policy2020

Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.

Christer F Aas, Jørn Henrik Vold, Svetlana Skurtveit, Ingvild Odsbu, Fatemeh Chalabianloo, Aaron G Lim, Kjell Arne Johansson, Lars Thore Fadnes

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Substance abuse treatment, prevention, and policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Christer F AasDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway. christer.frode.aas@helse-bergen.no.ORCID 0000-0002-6469-9354
Jørn Henrik VoldDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Svetlana SkurtveitInstitute for Clinical Medicine, University of Oslo, Oslo, Norway.
Ingvild OdsbuDepartment of Medicine, Karolinska Institutet, Solna, Sweden.
Fatemeh ChalabianlooDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Aaron G LimPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Kjell Arne JohanssonDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Lars Thore FadnesDepartment of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Haukeland University Hospital · NOKarolinska Institutet · SENorwegian Institute of Public Health · NOUniversity of Bristol · GBUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT) programs. The objective of this study was to estimate and to compare HCV treatment uptake after the introduction of DAAs among patients receiving OAT in Sweden and Norway. We also aimed to evaluate predictors of DAAs treatment among OAT patients in both countries.

methodsThis observational study was conducted with data from The Swedish Prescribed Drug Register and The Norwegian Prescription Database. We studied dispensed medications to calculate HCV treatment among OAT patients from 2014 to 2017 in Sweden and Norway. HCV prevalence was estimated from primary and secondary sources. Dispensations of medicines from different therapeutic areas, which served as proxy for co-morbidities in 2017, were conditionally adjusted for age, gender, and OAT medications. Logistic regression was used to evaluate these parameters.

resultsIn total 3529 individuals were identified with dispensed OAT in the Swedish cohort and 7739 individuals in the Norwegian cohort. HCV treatment was utilized by 407 persons in Sweden and 920 in Norway during the study period. Annual HCV and DAA treatment uptake increased in both countries. The estimated cumulative HCV treatment uptake at the end of 2017 was 31% in Norway and 28% in Sweden. DAA treatment was associated with increased age (aOR 1.8; 95% CI 1.0-3.2) and the dispensation of drugs used for diabetes (aOR 3.2; 95% CI 1.8-5.7) in Sweden. In Norway, lipid modifying agents and antibacterials were associated with decreased odds (aOR 0.4; 95%CI 0.2-0.9, aOR 0.8; 95%CI 0.6-1.0).

conclusionsAn increase in DAA treatment and HCV treatment uptake was observed among Swedish and Norwegian OAT patients whilst introducing new direct-acting antiviral treatment regimens. However, more than two thirds of the OAT population in Norway and Sweden were untreated at the beginning of 2018. A further scale-up is crucial in order to control and eliminate the HCV endemic among OAT patients.

Indexed as

AdolescentAdultAgedAge FactorsAntiviral AgentsComorbidityDrug UtilizationFemaleHepatitis C, ChronicHumansMaleMiddle AgedNorwayOpiate Substitution TreatmentSubstance Abuse, IntravenousSwedenAntiviral AgentsChronic hepatitis CDirect-acting antiviralsHepatitis COpioid substitution treatmentTreatment uptake

Identifiers

PMID32605625
PMCPMC7325258
OpenAlexW3037761207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.